Optimi Health Adds Risk Management Veteran Jason Mosberian to Board

An update from Optimi Health ( (TSE:OPTI) ) is now available.

Optimi Health has appointed Jason Mosberian to its board of directors, replacing outgoing director Jonathan Schintler, with the move subject to Canadian Securities Exchange approval. Mosberian, a CPA and Senior Vice President and Partner at BFL Canada, brings more than a decade of experience in risk management and insurance across manufacturing, distribution and life sciences, bolstering governance and risk oversight at the psychedelic drug manufacturer as it expands its regulated pharmaceutical operations.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Spark’s Take on TSE:OPTI Stock

According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.

Optimi Health’s overall score is primarily impacted by its financial performance, which shows potential but is hindered by persistent losses and cash flow challenges. Technical analysis provides some positive momentum signals, but valuation concerns due to negative earnings weigh heavily on the score.

To see Spark’s full report on TSE:OPTI stock, click here.

More about Optimi Health

Optimi Health Corp. is a Canadian Good Manufacturing Practices-compliant pharmaceutical drug manufacturer licensed by Health Canada to handle controlled substances and produce GMP-grade active pharmaceutical ingredients and finished dosage forms. Operating from two 10,000-square-foot facilities in British Columbia under a Drug Establishment License, the company supplies MDMA and psilocybin-based products to regulated channels, including prescription markets in Australia via the Authorized Prescriber Scheme and special access pathways in Canada.

Average Trading Volume: 109,058

Technical Sentiment Signal: Buy

Current Market Cap: C$30.44M

Find detailed analytics on OPTI stock on TipRanks’ Stock Analysis page.